Search results for "acute myeloid leukemia"

showing 10 items of 35 documents

Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study

2015

Abstract Background: Acute promyelocytic leukemia (APL) is a rare subtype of childhood acute myeloid leukemia (AML). Bleeding complications occur in 80% of patients at diagnosis and contribute to a higher incidence of early death (ED) in APL compared to other AML subtypes. However, estimates of ED in pediatric APL are imprecise and factors associated with ED in children with APL are unknown. Objectives: To determine the incidence and predictors of ED, defined as death within 60 days from presentation, in childhood APL. Methods: We conducted a retrospective international analysis of children diagnosed with APL between January 1993 and December 2013. The study included 236 patients from the I…

Acute promyelocytic leukemiaPediatricsmedicine.medical_specialtybusiness.industryIncidence (epidemiology)ImmunologyChildhood Acute Myeloid LeukemiaRetrospective cohort studyCell BiologyHematologyOdds ratiomedicine.diseaseBiochemistryClinical trialmedicinebusinessBody mass indexLung allocation scoreBlood
researchProduct

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-0…

2016

The aim of this clinical trial was to evaluate the impact of all-trans retinoic acid (ATRA) in combination with chemotherapy and to assess the NPM1 status as biomarker for ATRA therapy in younger adult patients (18–60 years) with acute myeloid leukemia (AML). Patients were randomized for intensive chemotherapy with or without open-label ATRA (45 mg/m2, days 6–8; 15 mg/m2, days 9–21). Two cycles of induction therapy were followed by risk-adapted consolidation with high-dose cytarabine or allogeneic hematopoietic cell transplantation. Due to the open label character of the study, analysis was performed on an intention-to-treat (ITT) and a per-protocol (PP) basis. One thousand one hundred pati…

AdultMale0301 basic medicineAcute promyelocytic leukemiaOncologymedicine.medical_specialtyNPM1Adolescentmedicine.medical_treatmentTretinoinYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansddc:610ChemotherapyAcute myeloid leukemiaHematologyAll-trans retinoic acidbusiness.industryMyeloid leukemiaInduction ChemotherapyHematologyGeneral MedicineMiddle Agedmedicine.disease3. Good healthSurgerySurvival RateTransplantationClinical trialLeukemia Myeloid AcuteTreatment Outcome030104 developmental biologyNucleophosmin-1Acute myeloid leukemia; All-trans retinoic acid; Nucleophosmin-1030220 oncology & carcinogenesisCytarabineFemaleOriginal ArticlebusinessNucleophosminFollow-Up Studiesmedicine.drug
researchProduct

Bone marrowVEGFCexpression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with sur…

2018

Vascular endothelial growth factor C (VEGFC) stimulates leukemia cell proliferation and survival, and promotes angiogenesis. We studied VEGFC expression in bone marrow samples from 353 adult acute myeloid leukemia (AML) patients and its relationship with several clinical, cytogenetic, and molecular variables. We also studied the expression of 84 genes involved in VEGF signaling in 24 patients. We found that VEGFC expression was higher in AML patients with myelodysplasia-related changes (AML-MRC) than in patients with non-AML-MRC. We also found an association between VEGFC expression and the patient cytogenetic risk group, with those with a worse prognosis having higher VEGFC expression leve…

AdultMale0301 basic medicineCancer ResearchAdolescentAngiogenesisVascular Endothelial Growth Factor CKaplan-Meier EstimateVEGFC expressionYoung Adult03 medical and health sciences0302 clinical medicineKDRBone Marrowhemic and lymphatic diseasesNeuropilin 1Biomarkers TumormedicineNRP1HumansGeneFLT1AgedChromosome AberrationsAcute myeloid leukemiaVascular Endothelial Growth Factor Receptor-1Cell growthbusiness.industryAdult Acute Myeloid LeukemiaHematologyVEGF signalingMiddle AgedPrognosismedicine.diseaseVascular Endothelial Growth Factor Receptor-2Neuropilin-1Leukemia Myeloid AcuteLeukemia030104 developmental biologymedicine.anatomical_structureOncologyVascular endothelial growth factor CMyelodysplastic Syndromes030220 oncology & carcinogenesisCancer researchFemaleBone marrowbusinessLeukemia & Lymphoma
researchProduct

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylatin…

2018

Patients with primary refractory or relapsed-acute myeloid leukemia (RR-AML), particularly older adults, have dismal outcomes and limited therapy options [1]. Given the tolerability of hypomethylat...

AdultMaleOncologyCancer Researchmedicine.medical_specialtyMyeloidAdolescentendocrine system diseasesmedicine.medical_treatmentHematopoietic stem cell transplantationRisk AssessmentYoung AdultRisk Factorshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTransplantation HomologousneoplasmsSurvival analysisAgedRetrospective StudiesAged 80 and overbusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisTransplantationLeukemia Myeloid AcuteLeukemiaTreatment Outcomemedicine.anatomical_structureOncologyTolerabilityHypomethylating agentDrug Resistance Neoplasmhypomethylating agent acute myeloid leukemia.FemaleNeoplasm Recurrence LocalbusinessLeukemia & Lymphoma
researchProduct

Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H- DNMT3A …

2018

Abstract Background Therapy-related acute myeloid leukemia (t-AML) develops in patients with prior exposure to cytotoxic therapies. Selection of a pre-existing TP53 mutated clone prone to acquire additional mutational events has been suggested as the main pathogenic mechanism of t-AML. Here, we report a unique case of t-AML which developed from a pre-existing DNMT3A mutated clone that persisted in the patient for more than 10 years despite treatment with intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (alloHSCT). Case presentation A 42-year-old male was diagnosed with AML harboring a normal karyotype and mutations in the NPM1 (c.863_864ins, p.W288 fs*12), DNMT3…

AdultMaleOncologymedicine.medical_specialtyNPM1Allogeneic transplantationmedicine.medical_treatmentClinical BiochemistryMutation MissenseClone (cell biology)Therapy-Related Acute Myeloid LeukemiaHematopoietic stem cell transplantationDNA Methyltransferase 3APathology and Forensic Medicine03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansTransplantation HomologousDNA (Cytosine-5-)-MethyltransferasesMolecular BiologyBone Marrow Transplantationbusiness.industryMyeloid leukemiaInduction chemotherapyTransplantationLeukemia Myeloid Acute030220 oncology & carcinogenesisbusinessNucleophosmin030215 immunologyExperimental and Molecular Pathology
researchProduct

Release of IFNγ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells

2022

Abstract Purpose: The stromal and immune bone marrow (BM) landscape is emerging as a crucial determinant for acute myeloid leukemia (AML). Regulatory T cells (Treg) are enriched in the AML microenvironment, but the underlying mechanisms are poorly elucidated. Here, we addressed the effect of IFNγ released by AML cells in BM Treg induction and its impact on AML prognosis. Experimental Design: BM aspirates from patients with AML were subdivided according to IFNG expression. Gene expression profiles in INFγhigh and IFNγlow samples were compared by microarray and NanoString analysis and used to compute a prognostic index. The IFNγ release effect on the BM microenvironment was investigated in me…

Cancer ResearchBone Marrow CellsMesenchymal Stem CellsSettore MED/08 - Anatomia PatologicaT-Lymphocytes RegulatoryInterferon-gammaLeukemia Myeloid AcuteMiceOncologyBone Marrowhemic and lymphatic diseasesTumor MicroenvironmentAnimalsIFNγ Acute Myeloid Leukemia Bone Marrow Immune Microenvironment
researchProduct

Chemical and biological evaluation of cross-linked halloysite-curcumin derivatives

2020

Abstract Well designed and safe nano drug carrier systems are an important tool in biomedical applications. The combination of two or more drugs has been used in medicine both to enhance the therapeutic effect and to decrease the side effects of drugs. Biocompatible halloysite nanotubes, that possess two different surfaces, are a suitable nanomaterial for a simultaneous carrier and release of two drugs that can exert a synergistic effect against cancer cells. In this study, three curcumin derivatives and doxorubicin were loaded by supramolecular and covalent linkage at the lumen and external surface of the halloysite nanotubes. The obtained multifunctional systems were characterized by seve…

Drugmedia_common.quotation_subjectNanoparticle020101 civil engineering02 engineering and technologyengineering.materialHalloysite0201 civil engineeringchemistry.chemical_compoundGeochemistry and PetrologymedicineDoxorubicinCytotoxicitymedia_commonSettore CHIM/02 - Chimica FisicaHalloysite nanotubes Curcumin derivatives Dual drug delivery Antiproliferative activity Breast cancer cell lines and acute myeloid leukemia cell linesChemistryGeologySettore CHIM/06 - Chimica Organica021001 nanoscience & nanotechnology3. Good healthCancer cellBiophysicsengineeringCurcuminSettore BIO/14 - Farmacologia0210 nano-technologyDrug carriermedicine.drug
researchProduct

Natural Inhibitors of P-glycoprotein in AcuteMyeloid Leukemia

2023

Acute myeloid leukemia (AML) remains an insidious neoplasm due to the percentage of patients who develop resistance to both classic chemotherapy and emerging drugs. Multidrug resistance (MDR) is a complex process determined by multiple mechanisms, and it is often caused by the overexpression of efflux pumps, the most important of which is P-glycoprotein (P-gp). This mini-review aims to examine the advantages of using natural substances as P-gp inhibitors, focusing on four molecules: phytol, curcumin, lupeol, and heptacosane, and their mechanism of action in AML.

Inorganic Chemistrymultidrug resistanceOrganic ChemistrySettore BIO/14 - FarmacologiaGeneral Medicinenatural substancesPhysical and Theoretical Chemistryacute myeloid leukemiaP-glycoproteinMolecular BiologySpectroscopyCatalysisComputer Science Applications
researchProduct

Role of the protein phosphatase CD45 and lipid rafts in the maintenance of acute myeloblastic leukemiaand development of a new therapeutic treatment

2017

CD45 is a pan-leukocyte protein with tyrosine phosphatase activity involved in the regulation of cytokinereceptors in hematopoiesis, such as the GM-CSF. We report here on new chemical compound,Pyrido[4,3-b]quinoxaline (PyQ), which is a plasma membrane disrupting agent, as a potential drug fortreatment of acute myeloid leukemia (AML). Indeed, we show that the hematopoietic cell lines aremore sensitive to PyQ, compared with non- hematopoietic cell lines. Using HOXA9-MEIS1-transformed blasts from a mouse model to study AML and human primary AML samples, wediscovered that CD45, which is mainly found within plasma-membrane lipid rafts, is rapidly delocalizedafter treatment with PyQ compound. The…

Lipid raftAcute myeloid leukemia[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyLeucémie aiguës myéloblastiquesRadeaux lipidiquesGM-CSFCD45
researchProduct

Essential Oil Composition of

2019

Drug resistance is a major obstacle in antibiotic and antitumor chemotherapy. In response to the necessity to find new therapeutic strategies, plant secondary metabolites including essential oils (EOs) may represent one of the best sources. EOs in plants act as constitutive defenses against biotic and abiotic stress, and they play an important role in the pharmacology for their low toxicity, good pharmacokinetic and multitarget activity. In this context, natural products such as EOs are one of the most important sources of drugs used in pharmaceutical therapeutics. The aim of this paper was to identify the chemical composition of the essential oil of Alluaudia procera leaves, obtained by hy…

MagnoliopsidaMolecular StructureSpectrum AnalysisPhytochemicalsDrug ResistanceOils VolatileAntineoplastic AgentsArticleessential oilacute myeloid leukemia cellAnti-Bacterial AgentsDidiereaceaesucculent plantsMolecules (Basel, Switzerland)
researchProduct